Cefotaxime and ceftriaxone cerebrospinal fluid levels during treatment of bacterial meningitis in children.
Cefotaxime (CTX) and ceftriaxone (CRO) were compared for cerebrospinal fluid (CSF) penetration and antimicrobial efficacy in cases of bacterial meningitis in children. This was a comparative study of CRO (100mg/kg once daily) and CTX (50 mg/kg 6 hourly) in the treatment of children with bacterial meningitis. The aetiological agents included Streptococcus pneumoniae (SPn), Haemophilus influenzae type b (Hib) and Neisseria meningitidis (NMen). Minimum inhibitory concentrations (MICs) were measured. In 33 patients from whom a second CSF specimen was obtained, CSF was cultured and assayed for antibiotic concentration. Median MICs of CTX and CRO for SPn, Hib and NMen were 0.01 and 0.01 microg/mL, 0.004 and 0.002 microg/mL and 0.008 and 0.004 microg/mL, respectively. All 33 repeat lumbar puncture specimens were sterile. The lowest CSF level recorded (0.45 microg/mL for CTX) was 45 times the MIC (0.01 microg/mL). The highest levels (24-35 microg/mL for CRO) were up to 8750 times the MIC of the patient's causative organism. A wide range of CSF levels for both antibiotics was observed. Levels varied with post-dose interval and duration of illness. On the basis of these findings, clinicians should be reassured that repeat lumbar puncture is not recommended for the causative organisms in this study (i.e., for Hib, NMen and penicillin/cefotaxime/ceftriaxone fully-susceptible SPn).
Goldwater
Paul N
PN
Microbiology & Infectious Diseases Department, Children, Youth and Women's Health Service, The Women's & Children's Hospital, North Adelaide, South Australia, Australia. goldwaterp@mail.wch.sa.gov.au
D000900:Anti-Bacterial Agents / Q000134:cerebrospinal fluid* / Q000627:therapeutic use*; D002439:Cefotaxime / Q000134:cerebrospinal fluid* / Q000627:therapeutic use*; D002443:Ceftriaxone / Q000134:cerebrospinal fluid* / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005260:Female; D019741:Haemophilus influenzae type b; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D016920:Meningitis, Bacterial / Q000134:cerebrospinal fluid* / Q000188:drug therapy*; D008583:Meningitis, Haemophilus / Q000134:cerebrospinal fluid / Q000188:drug therapy; D008585:Meningitis, Meningococcal / Q000134:cerebrospinal fluid / Q000188:drug therapy; D008586:Meningitis, Pneumococcal / Q000134:cerebrospinal fluid / Q000188:drug therapy
D000900:Anti-Bacterial Agents; D002443:Ceftriaxone; D002439:Cefotaxime